{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:14:52Z","timestamp":1793124892321,"version":"4.5.0"},"reference-count":187,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jacasi.2025.04.010","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:23:37Z","timestamp":1751430217000},"page":"821-846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Position Statement on Antiplatelet Therapy for East Asians With Coronary Artery Disease"],"prefix":"10.1016","volume":"5","author":[{"given":"Yanjun","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0403-3726","authenticated-orcid":false,"given":"Young-Hoon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzung-Dau","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack Wei Chieh","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juying","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yundai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuyi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tse-Min","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-9316","authenticated-orcid":false,"given":"Jiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Sidney C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9360-7332","authenticated-orcid":false,"given":"Junbo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacasi.2025.04.010_bib1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/eurjpc\/zwab213","article-title":"Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990-2019","volume":"29","author":"Safiri","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12928-020-00642-w","article-title":"Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective","volume":"35","author":"Mangieri","year":"2020","journal-title":"Cardiovasc Interv Ther"},{"key":"10.1016\/j.jacasi.2025.04.010_bib3","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jacc.2021.06.012","article-title":"De-escalation of dual antiplatelet therapy in patients with acute coronary syndromes","volume":"78","author":"Shoji","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib5","first-page":"1082","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"70","author":"Ib\u00e1nez","year":"2017","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.jacasi.2025.04.010_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ejcts\/ezx334","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"53","author":"Valgimigli","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jacasi.2025.04.010_bib7","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib8","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"11","author":"Levine","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.jacasi.2025.04.010_bib11","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3390\/jcm9061963","article-title":"Antithrombotic strategy for patients with acute coronary syndrome: a perspective from East Asia","volume":"9","author":"Numasawa","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.4070\/kcj.2018.0166","article-title":"The evolving concept of dual antiplatelet therapy after percutaneous coronary intervention: focus on unique feature of East Asian and \"Asian Paradox\"","volume":"48","author":"Kang","year":"2018","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.scib.2018.12.020","article-title":"2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"64","author":"Huo","year":"2019","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.jacasi.2025.04.010_bib14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ehjcvp\/pvad032","article-title":"Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease","volume":"9","author":"Valgimigli","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacasi.2025.04.010_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/ehjcvp\/pvad016","volume":"9","author":"Navarese","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacasi.2025.04.010_bib16","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"Kim","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib18","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacasi.2025.04.010_bib19","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacasi.2025.04.010_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008307","article-title":"Application of the academic research consortium high bleeding risk criteria in an all-comers registry of percutaneous coronary intervention","volume":"12","author":"Natsuaki","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacasi.2025.04.010_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.thromres.2021.11.015","article-title":"Validation of the Academic Research Consortium for High Bleeding Risk criteria in Chinese patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention","volume":"209","author":"Lyu","year":"2022","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.jacasi.2025.04.010_bib22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3390\/jcm11040988","article-title":"Temporal trends of major bleeding and its prediction by the Academic Research Consortium-high bleeding risk criteria in acute myocardial infarction","volume":"11","author":"Byun","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib23","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.4244\/EIJ-D-21-00181","article-title":"Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition","volume":"17","author":"Gragnano","year":"2021","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacasi.2025.04.010_bib24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1253\/circj.CJ-19-1109","article-title":"JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease","volume":"84","author":"Nakamura","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5551\/jat.63576","article-title":"Validation of the domestic high bleeding risk criteria for Japanese patients with acute myocardial infarction","volume":"30","author":"Matsumoto","year":"2023","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacasi.2025.04.010_bib26","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1007\/s00380-021-01836-9","article-title":"Prevalence of the Japanese high bleeding risk criteria and its prognostic significance for fatal bleeding in patients with acute myocardial infarction","volume":"36","author":"Sotomi","year":"2021","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jacasi.2025.04.010_bib27","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.15420\/ecr.2020.45","article-title":"2020 Asian Pacific Society of Cardiology consensus recommendations on antithrombotic management for high-risk chronic coronary syndrome","volume":"16","author":"Tan","year":"2021","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib28","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1055\/s-0039-1688792","article-title":"Development and validation of an ischemic and bleeding risk evaluation tool in East Asian patients receiving percutaneous coronary intervention","volume":"119","author":"Kang","year":"2019","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1016\/j.jacasi.2025.04.010_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008708","article-title":"Prediction of thrombotic and bleeding events after percutaneous coronary intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores","volume":"7","author":"Natsuaki","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacasi.2025.04.010_bib30","first-page":"1194","article-title":"A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study","volume":"93","author":"Chen","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jacasi.2025.04.010_bib31","doi-asserted-by":"crossref","DOI":"10.54912\/jci.2024.0006","article-title":"\"East Asian Paradox\" Revisited: Precision Medicine for Antithrombotic Strategies Tailored to Atherothrombotic Cardiovascular Risks","volume":"3","author":"Jeong","year":"2024","journal-title":"J Cardiovasc Interv"},{"key":"10.1016\/j.jacasi.2025.04.010_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jacasi.2021.11.014","article-title":"Residual inflammatory risk and its association with events in East Asian Patients after coronary intervention","volume":"2","author":"Ahn","year":"2022","journal-title":"JACC Asia"},{"issue":"23","key":"10.1016\/j.jacasi.2025.04.010_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313079","article-title":"Current and novel antiplatelet therapies for the treatment of cardiovascular diseases","volume":"22","author":"Jourdi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacasi.2025.04.010_bib34","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)02391-6","article-title":"Acute coronary syndromes","volume":"399","author":"Bergmark","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib35","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial","volume":"149","author":"Natsuaki","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib36","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.667584","article-title":"Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1","volume":"115","author":"Faraday","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib37","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib38","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00002512-200118050-00007","article-title":"Indobufen: an updated review of its use in the management of atherothrombosis","volume":"18","author":"Bhana","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jacasi.2025.04.010_bib40","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/CIRCULATIONAHA.122.062762","article-title":"Indobufen or aspirin on top of clopidogrel after coronary drug-eluting stent implantation (OPTION): a randomized, open-label, end point-blinded, noninferiority trial","volume":"147","author":"Wu","year":"2023","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.jacasi.2025.04.010_bib41","doi-asserted-by":"crossref","first-page":"8977","DOI":"10.3390\/ijerph19158977","article-title":"Ideal P2Y12 inhibitor in acute coronary syndrome: a review and current status","volume":"19","author":"Pradhan","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jacasi.2025.04.010_bib42","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib43","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib44","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","article-title":"Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study","volume":"294","author":"Sabatine","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacasi.2025.04.010_bib45","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacasi.2025.04.010_bib46","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2019.09.011","article-title":"Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients","volume":"290","author":"Sun","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacasi.2025.04.010_bib48","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/cpt.2011","article-title":"Efficacy and safety of ticagrelor vs clopidogrel in East Asian patients with acute myocardial infarction: a nationwide cohort study","volume":"109","author":"Chang","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacasi.2025.04.010_bib49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/11595930-000000000-00000","article-title":"Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study","volume":"32","author":"Li","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jacasi.2025.04.010_bib50","doi-asserted-by":"crossref","first-page":"666","DOI":"10.5414\/CP202549","article-title":"Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes","volume":"54","author":"Li","year":"2016","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jacasi.2025.04.010_bib51","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib52","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","article-title":"Ticagrelor vs clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome\u2014randomized, double-blind, phase III PHILO study","volume":"79","author":"Goto","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib53","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","article-title":"Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial","volume":"140","author":"Park","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib54","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib55","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012078","article-title":"Safety and effectiveness of contemporary P2Y(12) inhibitors in an East Asian population with acute coronary syndrome: a nationwide population-based cohort study","volume":"8","author":"Yun","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacasi.2025.04.010_bib56","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2004","article-title":"Ischemic and bleeding events among patients with acute coronary syndrome associated with low-dose prasugrel vs standard-dose clopidogrel treatment","volume":"3","author":"Shoji","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacasi.2025.04.010_bib57","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/CIRCULATIONAHA.120.051700","article-title":"Durable polymer versus biodegradable polymer drug-eluting stents after percutaneous coronary intervention in patients with acute coronary syndrome: the HOST-REDUCE-POLYTECH-ACS trial","volume":"143","author":"Kim","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124399","article-title":"Impact of body mass index on in-hospital complications in patients undergoing percutaneous coronary intervention in a Japanese real-world multicenter registry","volume":"10","author":"Numasawa","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jacasi.2025.04.010_bib59","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.amjcard.2010.01.349","article-title":"Difference in patient profiles and outcomes in Japanese versus American patients undergoing coronary revascularization (collaborative study by CREDO-Kyoto and the Texas Heart Institute Research Database)","volume":"105","author":"Kohsaka","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib60","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ahj.2015.09.017","article-title":"An international comparison of patients undergoing percutaneous coronary intervention: A collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database-Keio interhospital Cardiovascular Studies (JCD-KiCS)","volume":"170","author":"Kohsaka","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib61","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011017","article-title":"Comparison of outcomes after percutaneous coronary intervention in elderly patients, including 10 628 nonagenarians: insights from a Japanese Nationwide Registry (J-PCI Registry)","volume":"8","author":"Numasawa","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacasi.2025.04.010_bib62","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1080\/09537104.2022.2118250","article-title":"Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry","volume":"33","author":"Xi","year":"2022","journal-title":"Platelets"},{"key":"10.1016\/j.jacasi.2025.04.010_bib63","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10557-021-07187-x","article-title":"Cilostazol: a review of basic mechanisms and clinical uses","volume":"36","author":"Kherallah","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacasi.2025.04.010_bib64","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1161\/CIRCULATIONAHA.108.822791","article-title":"Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"119","author":"Chen","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib65","first-page":"1s","article-title":"[2018 ESC\/EACTS guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS)]","volume":"20","author":"Neumann","year":"2019","journal-title":"G Ital Cardiol (Rome)"},{"key":"10.1016\/j.jacasi.2025.04.010_bib66","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib67","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib68","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacasi.2025.04.010_bib69","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jacasi.2025.04.010_bib70","first-page":"1671","article-title":"Geographical variations in the effectiveness and safety of abbreviated or standard antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk","volume":"40","author":"Ozaki","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib71","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacasi.2025.04.010_bib72","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib73","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/CIRCULATIONAHA.123.064264","article-title":"Comparison of 3- to 6-month versus 12-month dual antiplatelet therapy after coronary intervention using the contemporary drug-eluting stents with ultrathin struts: the HOST-IDEA randomized clinical trial","volume":"147","author":"Han","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib74","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41569-023-00901-2","article-title":"De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis","volume":"20","author":"Gorog","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib75","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1161\/CIRCULATIONAHA.118.033983","article-title":"Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease: results of the SWAP-4 study","volume":"137","author":"Franchi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib76","first-page":"432","article-title":"Expert Consensus statement on dual antiplatelet therapy in patients with coronary artery disease]","volume":"49","year":"2021","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"10.1016\/j.jacasi.2025.04.010_bib77","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib78","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib79","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib80","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacasi.2025.04.010_bib81","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib82","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1093\/eurheartj\/ehab741","article-title":"Chinese expert consensus statement on dual antiplatelet therapy in patients with coronary artery disease","volume":"43","author":"Han","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib83","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.jcin.2019.07.011","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in PCI","volume":"12","author":"Pauley","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.jacasi.2025.04.010_bib84","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib85","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib86","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0877","article-title":"P2Y12 inhibitor monotherapy vs dual antiplatelet therapy after deployment of a drug-eluting stent: the SHARE randomized clinical trial","volume":"7","author":"Min","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacasi.2025.04.010_bib87","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Ge","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib88","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib89","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1055\/s-0043-57030","article-title":"Comparison of de-escalation of DAPT intensity or duration in East Asian and Western patients with ACS undergoing PCI: a systematic review and meta-analysis","volume":"123","author":"Gorog","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacasi.2025.04.010_bib90","first-page":"680","article-title":"[Guideline on the diagnosis and treatment of stable coronary artery disease]","volume":"46","year":"2018","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"10.1016\/j.jacasi.2025.04.010_bib91","first-page":"81","article-title":"Interpretation of 2019 ESC guidelines for chronic coronary syndrome","volume":"25","author":"Guo","year":"2023","journal-title":"Chin Circ J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib92","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib93","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib94","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib95","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib96","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(20)32236-4","article-title":"Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial","volume":"396","author":"Silvain","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib97","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib98","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/bmj.328.7437.434","article-title":"Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice","volume":"328","author":"Jenkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jacasi.2025.04.010_bib99","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40119-022-00255-9","article-title":"Coronary artery disease and aspirin intolerance: background and insights on current management","volume":"11","author":"Thakker","year":"2022","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.jacasi.2025.04.010_bib100","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib101","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial","volume":"397","author":"Koo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib102","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/CIRCULATIONAHA.122.062770","article-title":"Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study","volume":"147","author":"Kang","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib103","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamacardio.2024.0534","article-title":"Extended clopidogrel monotherapy vs DAPT in patients with acute coronary syndromes at high ischemic and bleeding risk: the OPT-BIRISK randomized clinical trial","volume":"9","author":"Li","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib104","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y(12) inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/eurheartj\/ehac515","article-title":"Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 update by the ESC Working Group on Thrombosis","volume":"44","author":"Andreotti","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib106","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","article-title":"Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial","volume":"395","author":"Gimbel","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib107","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1161\/CIRCULATIONAHA.120.050645","article-title":"Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART registry","volume":"142","author":"Szummer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib108","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac231","article-title":"In-hospital outcomes of ticagrelor versus clopidogrel in patients 75 years or older with acute coronary syndrome: findings from the Improving Care for Cardiovascular Disease in China (CCC)-Acute Coronary Syndrome Project","volume":"51","author":"Yang","year":"2022","journal-title":"Age Ageing"},{"key":"10.1016\/j.jacasi.2025.04.010_bib109","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","article-title":"Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study","volume":"390","author":"Li","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib110","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jacc.2021.10.028","article-title":"Magnetically controlled capsule endoscopy for assessment of antiplatelet therapy-induced gastrointestinal injury","volume":"79","author":"Han","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib111","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Monotherapy with a P2Y(12) inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib112","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","volume":"375","author":"Johnston","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib113","doi-asserted-by":"crossref","first-page":"e1605","DOI":"10.4244\/EIJ-D-19-00699","article-title":"Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial","volume":"15","author":"Tomaniak","year":"2020","journal-title":"EuroIntervention"},{"issue":"5","key":"10.1016\/j.jacasi.2025.04.010_bib114","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.3390\/jcm12052082","article-title":"Antiplatelet strategies for older patients with acute coronary syndromes: finding directions in a low-evidence field","volume":"12","author":"De Servi","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib115","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehn579","article-title":"Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications","volume":"30","author":"Schmitt","year":"2009","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.jacasi.2025.04.010_bib116","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.116.004395","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective-2016 update","volume":"9","author":"Angiolillo","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacasi.2025.04.010_bib117","doi-asserted-by":"crossref","first-page":"I43","DOI":"10.1093\/eurheartjsupp\/suac072","article-title":"Therapeutic uncertainties: first finding of atrial fibrillation in acute coronary syndrome","volume":"24","author":"Greco","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.jacasi.2025.04.010_bib118","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib119","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib120","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib121","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data","volume":"374","author":"S\u00f8rensen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib122","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/clc.22411","article-title":"Antithrombotic regimens for patients taking oral anticoagulation after coronary intervention: a meta-analysis of 16 clinical trials and 9,185 patients","volume":"38","author":"Gao","year":"2015","journal-title":"Clin Cardiol"},{"issue":"14","key":"10.1016\/j.jacasi.2025.04.010_bib123","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/eurheartj\/ehad863","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"45","author":"Byrne","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib124","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials","volume":"4","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib125","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib126","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib127","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib128","first-page":"486","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"378","author":"Piccini","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib129","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib130","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib131","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib132","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.120.046534","article-title":"Risk\/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS","volume":"141","author":"Alexander","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib133","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib134","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009535","article-title":"Quantifying the risk of heart disease following acute ischaemic stroke: a meta-analysis of over 50,000 participants","volume":"6","author":"Gunnoo","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacasi.2025.04.010_bib136","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib137","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(20)30079-X","article-title":"Prevalence, predictors, and prognosis of symptomatic intracranial stenosis in patients with transient ischaemic attack or minor stroke: a population-based cohort study","volume":"19","author":"Hurford","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib138","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(13)70195-9","article-title":"Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment","volume":"12","author":"Holmstedt","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib139","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/STROKEAHA.113.003508","article-title":"Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study","volume":"45","author":"Wang","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.jacasi.2025.04.010_bib140","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ana.21768","article-title":"Intracranial atherosclerotic disease: an update","volume":"66","author":"Qureshi","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib141","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1105335","article-title":"Stenting versus aggressive medical therapy for intracranial arterial stenosis","volume":"365","author":"Chimowitz","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib142","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/eurheartj\/eht042","article-title":"Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy","volume":"34","author":"Agewall","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib143","first-page":"813","article-title":"Multidisciplinary expert consensus on the prevention and management of bleeding in patients with acute coronary syndrome receiving antithrombotic agents]","volume":"55","year":"2016","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.jacasi.2025.04.010_bib144","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00535-010-0299-0","article-title":"Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding","volume":"46","author":"Tsai","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib145","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ijcard.2013.06.135","article-title":"Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial","volume":"168","author":"DiNicolantonio","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-152-1-201001050-00179","article-title":"Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial","volume":"152","author":"Sung","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib147","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1155\/2009\/509258","article-title":"Acetylsalicylic acid use in patients with acute myocardial infarction and peptic ulcer bleeding","volume":"23","author":"Cheung","year":"2009","journal-title":"Can J Gastroenterol"},{"issue":"24","key":"10.1016\/j.jacasi.2025.04.010_bib148","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib149","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.14599","article-title":"Reintroduction of anti-thrombotic therapy after a gastrointestinal haemorrhage: if and when?","volume":"177","author":"Scott","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib151","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4166\/kjg.2020.76.3.108","article-title":"[Clinical guidelines for drug-induced peptic ulcer, 2020 revised edition]","volume":"76","author":"Joo","year":"2020","journal-title":"Korean J Gastroenterol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib152","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00535-021-01769-0","article-title":"Evidence-based clinical practice guidelines for peptic ulcer disease 2020","volume":"56","author":"Kamada","year":"2021","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib153","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCULATIONAHA.109.865352","volume":"121","author":"Fox","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib154","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.amjms.2021.10.034","article-title":"Estimated glomerular filtration rate derived from different formulas and prognosis in acute coronary syndrome: Findings from the improving care for cardiovascular disease in China-acute coronary syndrome project","volume":"364","author":"Lin","year":"2022","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jacasi.2025.04.010_bib155","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","article-title":"Chronic kidney disease and coronary artery disease: JACC state-of-the-art review","volume":"74","author":"Sarnak","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib156","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtha.2023.09.020","article-title":"Anticoagulation in chronic kidney disease: current status and future perspectives","volume":"22","author":"Jones","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacasi.2025.04.010_bib157","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.hjr.0000220582.19516.a6","article-title":"Renal function and outcomes in acute coronary syndrome: impact of clopidogrel","volume":"14","author":"Keltai","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.jacasi.2025.04.010_bib158","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.kint.2016.09.014","article-title":"Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease","volume":"91","author":"Carrero","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacasi.2025.04.010_bib159","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40256-020-00447-5","article-title":"Long-term antithrombotic therapy and clinical outcomes in patients with acute coronary syndrome and renal impairment: insights from EPICOR and EPICOR Asia","volume":"21","author":"Huo","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacasi.2025.04.010_bib160","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012236","article-title":"Safety of dual-antiplatelet therapy after myocardial infarction among patients with chronic kidney disease","volume":"8","author":"Rymer","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacasi.2025.04.010_bib161","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/clc.22063","article-title":"Angiotensin receptor blockers worsen renal function and dyspnea on ticagrelor: a potential ticagrelor-angiotensin receptor blocker interaction?","volume":"35","author":"DiNicolantonio","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib162","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00380-022-02029-8","article-title":"Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT)","volume":"37","author":"Graham","year":"2022","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jacasi.2025.04.010_bib163","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2215\/CJN.12901018","article-title":"Duration of dual antiplatelet therapy in patients with CKD and drug-eluting stents: a meta-analysis","volume":"14","author":"Mavrakanas","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib164","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11239-023-02940-5","article-title":"Antithrombotic strategies for preventing graft failure in coronary artery bypass graft","volume":"57","author":"Mauro","year":"2024","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacasi.2025.04.010_bib165","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020413","article-title":"Dual antiplatelet therapy with clopidogrel and aspirin versus aspirin monotherapy in patients undergoing coronary artery bypass graft surgery","volume":"10","author":"Qu","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacasi.2025.04.010_bib166","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib167","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/jama.2018.3197","article-title":"Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: a randomized clinical trial","volume":"319","author":"Zhao","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jacasi.2025.04.010_bib168","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1161\/CIRCULATIONAHA.120.050749","article-title":"Effect of adding ticagrelor to standard aspirin on saphenous vein graft patency in patients undergoing coronary artery bypass grafting (POPular CABG): a randomized, double-blind, placebo-controlled trial","volume":"142","author":"Willemsen","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.04.010_bib169","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jacc.2010.10.029","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial","volume":"57","author":"Held","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2012.03.030","article-title":"Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis","volume":"60","author":"Smith","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib171","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1007\/s12325-020-01376-0","article-title":"Dual antiplatelet therapy duration in medically managed acute coronary syndrome patients: sub-analysis of the OPT-CAD study","volume":"37","author":"Ma","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacasi.2025.04.010_bib172","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ahj.2008.09.026","article-title":"Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study","volume":"157","author":"Bi","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacasi.2025.04.010_bib173","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2025.04.010_bib174","doi-asserted-by":"crossref","first-page":"330","DOI":"10.34172\/jcvtr.2021.52","article-title":"Adherence to dual antiplatelet therapy after coronary stenting: a study conducted at two Vietnamese hospitals","volume":"13","author":"Tien Hoang","year":"2021","journal-title":"J Cardiovasc Thorac Res"},{"key":"10.1016\/j.jacasi.2025.04.010_bib175","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1093\/pubmed\/fdy088","article-title":"Adherence to cardiovascular medication: a review of systematic reviews","volume":"41","author":"Leslie","year":"2019","journal-title":"J Public Health (Oxf)"},{"key":"10.1016\/j.jacasi.2025.04.010_bib176","first-page":"2590","article-title":"Exploration on adherence of secondary prevention of coronary heart disease patients and its influencing factors","volume":"33","author":"Huo","year":"2019","journal-title":"Chinese Nursing Research"},{"key":"10.1016\/j.jacasi.2025.04.010_bib177","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.jacc.2019.03.470","article-title":"Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD: JACC review topic of the week","volume":"73","author":"Arora","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib178","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/ehjcvp\/pvy018","article-title":"Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry","volume":"4","author":"Zeymer","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacasi.2025.04.010_bib179","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000475705","article-title":"Incidence and causes for early ticagrelor discontinuation: a \"real-world\" Dutch Registry Experience","volume":"138","author":"Bergmeijer","year":"2017","journal-title":"Cardiology"},{"key":"10.1016\/j.jacasi.2025.04.010_bib180","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill strategy in secondary cardiovascular prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib181","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/jamacardio.2019.0897","article-title":"Effect of a quality of care improvement initiative in patients with acute coronary syndrome in resource-constrained hospitals in China: A randomized clinical trial","volume":"4","author":"Wu","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacasi.2025.04.010_bib182","first-page":"306","article-title":"Chinese expert consensus on clopidogrel\/aspirin single-pill combination antiplatelet therapy","volume":"29","year":"2021","journal-title":"Chinese Journal of Interventional Cardiology"},{"key":"10.1016\/j.jacasi.2025.04.010_bib183","first-page":"527","article-title":"The use of antiplatelet agents after an acute coronary syndrome in a large community Italian setting of more than 12 million subjects","volume":"8","author":"Maggioni","year":"2019","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.jacasi.2025.04.010_bib184","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.jacasi.2023.07.008","article-title":"Low-dose aspirin for primary prevention of cardiovascular events comparing East Asians with Westerners: a meta-analysis","volume":"3","author":"Kim","year":"2023","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacasi.2025.04.010_bib185","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.jcin.2023.08.019","article-title":"Dyspnea-related ticagrelor discontinuation after percutaneous coronary intervention","volume":"16","author":"Angiolillo","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacasi.2025.04.010_bib186","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1053867","article-title":"Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome","volume":"9","author":"Kang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacasi.2025.04.010_bib187","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/ehjcvp\/pvaa005","article-title":"Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention","volume":"7","author":"Lee","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374725002704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374725002704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T05:45:00Z","timestamp":1757655900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772374725002704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":187,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2772374725002704"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2025.04.010","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Position Statement on Antiplatelet Therapy for East Asians With Coronary Artery Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2025.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}